Pembrolizumab in Locally Advanced Sinonasal Carcinoma — NeoPeSino

Sinonasal Undifferentiated Carcinoma Clinical Trial

Official title:
Neoadjuvant Pembrolizumab Plus Chemotherapy in Locally Advanced Sinonasal Carcinoma

Status Not yet recruiting

Clinical Trial Summary

This study will test the Safety and activity of pembrolizumab plus chemotherapy as neoadjuvant treatment in locally advanced sinonasal undifferentiated carcinoma (SNUC). Activity of neoadjuvant chemotherapy in locally advanced SNUC has been already demonstrated; the primary hypothesis is that the addition of pembrolizumab as neoadjuvant and adjuvant agent might confirm the results obtained with a combined treatment strategy including chemotherapy, decreasing the burden of treatment-related side effects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma
Sinonasal Undifferentiated Carcinoma

Clinical Trial Details

NCT number	NCT05925491
Study type	Interventional
Source	Istituti Clinici Scientifici Maugeri SpA
Contact	Viola Ghio, M.Sc.
Phone	+39 (0)3982592326
Email	studiclinici.ot.pavia@icsmaugeri.it
Status	Not yet recruiting
Phase	Phase 2
Start date	November 2023
Completion date	November 2026

View Details

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT00707473` - Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer	Phase 2
	Active, not recruiting	`NCT01586767` - Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy	N/A